Advertisement

Increasing Rate of Hospital Admissions in Patients With Amyloidosis (from the National Inpatient Sample)

Published:September 10, 2019DOI:https://doi.org/10.1016/j.amjcard.2019.08.045
      Cardiac amyloidosis is an increasingly recognized cause of heart failure with preserved or mildly reduced ejection fraction with emerging treatment options. We sought to analyze the temporal trends and impact of hospital admissions in patients with amyloidosis. The National Inpatient Sample was queried to identify patients from 2005 to 2014 who were hospitalized with a diagnosis of amyloidosis using ICD9 codes. Trends over time of prevalence, demographics, co-morbidities, and outcomes were described. Propensity-matching was used to assess the impact of amyloidosis on in-hospital outcomes, including mortality. A total of 156,914 admissions in patients with amyloidosis (age 69.86 +/− 12.33 years, 45.7% female, 68.5% Caucasian) were identified. Hospitalizations more than doubled with a peak of 21,740 per year and 62 per 100,000 admissions in 2014. Over time, patients admitted with amyloidosis were older and more likely to have co-morbid medical conditions. A diagnosis of heart failure was present in 34.7% of patients, increased over time (p = 0.001), and was associated with further morbidity and mortality. In a propensity-matched analysis, patients admitted with amyloidosis had a longer length of stay (7.5 vs 6.2 days), were less likely to be discharged home (43.6% vs 48.7%), and were more likely to die during the hospitalization (7.4% vs 4.9%, p <0.001 for all). In conclusion, inpatient hospitalizations in the United States in patients with amyloidosis have increased over time and are associated with high morbidity and mortality, particularly when there is concomitant heart failure.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kyle RA
        • Larson DR
        • Kurtin PJ
        • Kumar S
        • Cerhan JR
        • Therneau TM
        • Rajkumar SV
        • Vachon CM
        • Dispenzieri A
        Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 through 2015.
        Mayo Clin Proc. 2019; 94: 465-471
        • Quock TP
        • Yan T
        • Chang E
        • Guthrie S
        • Broder MS
        Epidemiology of AL amyloidosis: a real-world study using US claims data.
        Blood Adv. 2018; 2: 1046-1053
        • Vranian MN
        • Sperry BW
        • Hanna M
        • Hachamovitch R
        • Ikram A
        • Brunken RC
        • Jaber WA
        Technetium pyrophosphate uptake in transthyretin cardiac amyloidosis: Associations with echocardiographic disease severity and outcomes.
        J Nucl Cardiol. 2018; 25: 1247-1256
        • Sperry BW
        • Tang WHW
        Amyloid heart disease: genetics translated into disease-modifying therapy.
        Heart Br Card Soc. 2017; 103: 812-817
      1. HCUP National (Nationwide) Inpatient Sample (NIS). Healthcare Cost and Utilization Project (HCUP). Available at: http://www.hcup-us.ahrq.gov/nisoverview.jsp. Accessed 19 November 2018.

        • Elixhauser A
        • Steiner C
        • Harris DR
        • Coffey RM
        Comorbidity measures for use with administrative data.
        Med Care. 1998; 36: 8-27
        • Kyle RA
        • Therneau TM
        • Rajkumar SV
        • Larson DR
        • Plevak MF
        • Offord JR
        • Dispenzieri A
        • Katzmann JA
        • Melton LJ
        Prevalence of monoclonal gammopathy of undetermined significance.
        N Engl J Med. 2006; 354: 1362-1369
        • Kyle RA
        • Therneau TM
        • Rajkumar SV
        • Offord JR
        • Larson DR
        • Plevak MF
        • Melton LJ
        A long-term study of prognosis in monoclonal gammopathy of undetermined significance.
        N Engl J Med. 2002; 346: 564-569
        • Kyle RA
        • Linos A
        • Beard CM
        • Linke RP
        • Gertz MA
        • O'Fallon WM
        • Kurland LT
        Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989.
        Blood. 1992; 79: 1817-1822
        • Quarta CC
        • Buxbaum JN
        • Shah AM
        • Falk RH
        • Claggett B
        • Kitzman DW
        • Mosley TH
        • Butler KR
        • Boerwinkle E
        • Solomon SD
        The Amyloidogenic V122I transthyretin variant in elderly black Americans.
        N Engl J Med. 2015; 372: 21-29
        • Schmidt HH
        • Waddington-Cruz M
        • Botteman MF
        • Carter JA
        • Chopra AS
        • Hopps M
        • Stewart M
        • Fallet S
        • Amass L
        Estimating the global prevalence of transthyretin familial amyloid polyneuropathy.
        Muscle Nerve. 2018; 57: 829-837
        • Tanskanen M
        • Peuralinna T
        • Polvikoski T
        • Notkola I-L
        • Sulkava R
        • Hardy J
        • Singleton A
        • Kiuru-Enari S
        • Paetau A
        • Tienari PJ
        • Myllykangas L
        Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study.
        Ann Med. 2008; 40: 232-239
        • Alexander KM
        • Orav J
        • Singh A
        • Jacob SA
        • Menon A
        • Padera RF
        • Kijewski MF
        • Liao R
        • Di Carli MF
        • Laubach JP
        • Falk RH
        • Dorbala S
        Geographic disparities in reported US amyloidosis mortality from 1979 to 2015: potential underdetection of cardiac amyloidosis.
        JAMA Cardiol. 2018; 3: 865-870
        • Sperry BW
        • Reyes BA
        • Ikram A
        • Donnelly JP
        • Phelan D
        • Jaber WA
        • Shapiro D
        • Evans PJ
        • Maschke S
        • Kilpatrick SE
        • Tan CD
        • Rodriguez ER
        • Monteiro C
        • Tang WHW
        • Kelly JW
        • Seitz WH
        • Hanna M
        Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release.
        J Am Coll Cardiol. 2018; 72: 2040-2050
        • Sperry BW
        • Ikram A
        • Hachamovitch R
        • Valent J
        • Vranian MN
        • Phelan D
        • Hanna M
        Efficacy of chemotherapy for light-chain amyloidosis in patients presenting with symptomatic heart failure.
        J Am Coll Cardiol. 2016; 67: 2941-2948
        • Merlini G
        • Dispenzieri A
        • Sanchorawala V
        • Schönland SO
        • Palladini G
        • Hawkins PN
        • Gertz MA
        Systemic immunoglobulin light chain amyloidosis.
        Nat Rev Dis Primer. 2018; 4: 38